All Over For Acorda After A Torrid Few Years

The embattled US biotech has gone into Chapter 11 and linked up with 'stalking horse' bidder Merz which has offered $185m to get hold of Ampyra for multiple sclerosis and Parkinson’s therapy Inbrija.

Dead end
• Source: Shutterstock

It is no longer a rare sight to see a biotech file for bankruptcy but it still raises the eyebrows when a firm established nearly 30 years ago which had a significant degree of success such as Acorda Therapeutics, Inc. goes out of business.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business